dual glp-1/glucagon receptor agonists Current Insights, Advantages and Challenges of Small Molecule Glucagon-like Peptide 1 Agonists: A Scoping Review Dual GLP-1/GIP receptor agonists mechanism

Scientists have now created long-lasting GLP-1 drugs that can be used to treat type 2 diabetes, obesity, and a range of other conditions

The first half of 2025 has confirmed a seismic shift in the pharmaceutical landscape: GLP-1 receptor agonists a class of new drug therapies for diabetes

GLP-Activate was designed to provide a constant stream of extracts and nutrients that may support healthy GLP-1 levels

What the EVOKE and EVOKE+ trials found At the 18th Clinical Trials on Alzheimers Disease (CTAD) conference (Dec

Methods Adults (18 years old) with T2D required at least one prescription for injectable semaglutide at index date (treatment switch), at least one prescription for any other GLP-1 RA in the previous 365 days, a baseline HbA1c and/or weight measurement in the 90 days pre-index and a follow-up measurement at 180 and 365 days post-index

| 228 comments on LinkedIn